BioLizard and AbnomX announce partnership

BioLizard’s custom advanced analytics services complement AbnomX’s innovative, user-friendly platform for deciphering immune repertoire data.

GHENT, Belgium April 2nd, 2024 – AbnomX and BioLizard announced a strategic partnership today. AbnomX are pioneers in the industrialization of antibody discovery and have developed their Antibody-Extractor platform to support scientists in transforming immune repertoire data into knowledge. BioLizard is a leading multi-national bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry and providing customized services to its biotech and pharma clients.

The complementarity of AbnomX’s innovative technologies and BioLizard’s tailored analytics services will enhance both companies’ efforts in supporting scientists active in sophisticated data-driven life sciences R&D: a perfect match of expertise by two companies originating from the biotech hub of Ghent.

With locations in Belgium, the Netherlands, Switzerland, and the US, BioLizard’s team of experts, “the Lizards,” specializes in helping biotech and pharma companies institute a biology-centric approach to digital transformation. The Lizards embody cross-domain expertise, pairing deep biomedical understanding with applied skills in data-driven approaches ranging from bioinformatics and AI to software development and data management. This allows BioLizard to apply specialist understanding to each client’s data environment and provide customized tools and insights that are aligned with the client’s strategic business goals. With the recent launch of their fully customizable Bio|Verse platform for biomedical data exploration, BioLizard has recently strengthened their services while maintaining true to their client-centric DNA.

Ghent-based AbnomX specializes in enabling researchers to obtain deep insights within immune repertoire research, helping them to transform complex data sets into useful knowledge for product development. AbnomX’s consultancy in immunoinformatics and antibody discovery is supported by their proprietary Antibody-Extractor platform, an in silico discovery platform that offers a suite of integrated and cross-talking modules for different steps of the discovery process, and their Abigael system for intelligent and convenient data management. Through an effective customer-friendly user interface, researchers can stitch together a natural workflow using fast, industry-standard algorithms. This allows scientists to obtain higher quality results faster, ultimately accelerating and optimizing their discovery and clinical development efforts.

Both companies have a strong track record in helping scientists to leverage large and complex biomedical datasets in order to extract insights that drive forward R&D. Together, BioLizard and AbnomX are convinced that their common data-driven, biology-centric focus and their complementary offerings will support scientists to streamline their antibody R&D and develop superior therapeutics faster.